Search

Your search keyword '"Scaldaferri, F"' showing total 736 results
Start Over Author "Scaldaferri, F"
736 results on '"Scaldaferri, F"'

2. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

3. OC.07.9: ENDOSCOPIC BALLOON DILATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN'S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE

Author

Lopetuso, L.R., primary, Coppola, G., additional, Alfieri, N., additional, Morretta, C., additional, Di Vincenzo, F., additional, Puca, P., additional, Parisio, L., additional, Marmo, C., additional, Settanni, C.R., additional, Laterza, L., additional, Pugliese, D., additional, Riccioni, M.E., additional, Cammarota, G., additional, Papa, A., additional, Gasbarrini, A., additional, and Scaldaferri, F., additional

Published
2024
Full Text
View/download PDF

5. T.05.4: RENAL LITHOGENIC RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES CORRELATES WITH MICROBIOTA COMPOSITION, URINARY PROFILE AND DIETARY INTAKE

Author

Mignini, I., primary, Blasi, V., additional, Masucci, L., additional, De Maio, F., additional, Agrillo, C., additional, Monzo, F.R., additional, Laterza, L., additional, Settanni, C.R., additional, Scaldaferri, F., additional, Napolitano, D., additional, Schiavoni, E., additional, D'Amato, D., additional, De Ninno, G., additional, Baroni, S., additional, Garcovich, M., additional, Riccardi, L., additional, Grassi, F., additional, Cintoni, M., additional, Mele, M.C., additional, Gasbarrini, A., additional, Ferraro, P.M., additional, and Papa, A., additional

Published
2024
Full Text
View/download PDF

6. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

8. OC.07.8: THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

Author

Del Gaudio, A., primary, Parisio, L., additional, Cuccia, G., additional, Privitera, G., additional, Laterza, L., additional, Lopetuso, L.R., additional, Rumi, G., additional, De Biasio, F., additional, Mignini, I., additional, Coppola, G., additional, Gasbarrini, A., additional, Scaldaferri, F., additional, and Pugliese, D., additional

Published
2024
Full Text
View/download PDF

9. T.08.9: SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION

Author

Capobianco, I., primary, Graziani, C., additional, Del Chierico, F., additional, Puca, P., additional, Di Vincenzo, F., additional, Wlderk, G., additional, Pirro, M.A., additional, Putignani, L., additional, Laterza, L., additional, Bibbò, S., additional, Petito, V., additional, Lopetuso, L.R., additional, Gasbarrini, A., additional, and Scaldaferri, F., additional

Published
2024
Full Text
View/download PDF

10. P715 Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictors

Author

Privitera, G, primary, Parisio, L, additional, Perniola, S, additional, Varca, S, additional, Alivernini, S, additional, Tolusso, B, additional, Petito, V, additional, Napolitano, D, additional, Schiavoni, E, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, Armuzzi, A, additional, Gremese, E, additional, Guidi, L, additional, and Pugliese, D, additional

Published
2024
Full Text
View/download PDF

11. P363 Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn’s disease treated with ustekinumab

Author

Mignini, I, primary, Maresca, R, additional, Esposto, G, additional, Ainora, M E, additional, Liguori, A, additional, Cintoni, M, additional, Galasso, L, additional, Laterza, L, additional, Lopetuso, L R, additional, Garcovich, M, additional, Riccardi, L, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Zocco, M A, additional

Published
2024
Full Text
View/download PDF

13. P109 Organic Cation Transporter (OCTN)-1 variants shape innate immunity and predict individual response to vedolizumab In ulcerative colitis patients

Author

Capobianco, I, primary, Puca, P, additional, Masi, L, additional, Petito, V, additional, Pafundi, P C, additional, De Felice, M, additional, Fidaleo, M, additional, Di Vincenzo, F, additional, Del Chierico, F, additional, Delogu, G, additional, Palucci, I, additional, Laterza, L, additional, Pizzoferrato, M, additional, Schiavoni, E, additional, Napolitano, D, additional, Turchini, L, additional, Amatucci, V, additional, Strazzeri, M, additional, Pugliese, D, additional, Putignani, L, additional, Armuzzi, A, additional, Lopetuso, L R, additional, Gasbarrini, A, additional, Pani, G, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

15. P881 Real-life vs trial access to biologic therapy differences: a 2019-2020 experience in an Italian tertiary IBD center

Author

DI VINCENZO, F, primary, Maresca, R, additional, Mora, V, additional, Petito, V, additional, Turchini, L, additional, Amatucci, V, additional, Napolitano, D, additional, Schiavoni, E, additional, Lopetuso, L R, additional, Parisio, L, additional, Settanni, C R, additional, Pizzoferrato, M, additional, Armuzzi, A, additional, Pugliese, D, additional, Laterza, L, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

16. P750 Endoscopic balloon dilation associated with biological therapy in Crohn's Disease strictures: a single center experience

Author

Lopetuso, L R, primary, Coppola, G, additional, Alfieri, N, additional, Morretta, C, additional, Di Vincenzo, F, additional, Puca, P, additional, Parisio, L, additional, Marmo, C, additional, Settanni, C R, additional, Laterza, L, additional, Pugliese, D, additional, Riccioni, M E, additional, Cammarota, G, additional, Papa, A, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

17. N06 Self-care in patients affected by inflammatory bowel disease: SELF-IBD observational study in a single center

Author

Napolitano, D, primary, Schiavoni, E, additional, Amatucci, V, additional, Monaci, A, additional, Martella, P, additional, Orgiana, N, additional, Benini, V, additional, Di Massimo, A, additional, Turchini, L, additional, Giordano, L N, additional, Conticelli, C, additional, Pettinari, V, additional, De Vito, A, additional, Virone, C, additional, Lorusso, A, additional, Fanali, C, additional, Ribaudi, E, additional, Bernabei, T, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Cocchieri, A, additional

Published
2024
Full Text
View/download PDF

18. P460 The POCER index: application of a novel endoscopic score in a real-life cohort of patients with Crohn's disease after surgery

Author

Parisio, L, primary, Del Gaudio, A, additional, Privitera, G, additional, Cuccia, G, additional, Lopetuso, L R, additional, Laterza, L, additional, Rumi, G, additional, De Biasio, F, additional, Mignini, I, additional, Calvez, V, additional, Coppola, G, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Pugliese, D, additional

Published
2024
Full Text
View/download PDF

19. P1203 Fecal transplantation for Ulcerative Colitis from diet conditioned donors followed by dietary intervention results in favorable gut microbial profile and decreased gut inflammation compared to fecal transplantation alone

Author

Leibovitzh, H, primary, Sarbagili Shabat, C, additional, Hirsch, A, additional, Zittan, E, additional, Mentella, M C, additional, Petito, V, additional, Cohen, N A, additional, Ron, Y, additional, Fliss Isakov, N, additional, Pfeffer, J, additional, Yaakov, M, additional, Fanali, C, additional, Turchini, L, additional, Masucci, L, additional, Quaranta, G, additional, Kolonimos, N, additional, Godneva, A, additional, Weinberger, A, additional, Scaldaferri, F, additional, and Maharshak, N, additional

Published
2024
Full Text
View/download PDF

20. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study

Author

Mocci, G, primary, Scaldaferri, F, additional, Pugliese, D, additional, Savarino, E, additional, Bodini, G, additional, Cuomo, A, additional, Donnarumma, L, additional, Maconi, G, additional, Cataletti, G, additional, Rodino, S, additional, Sebkova, L, additional, Ferronato, A, additional, Gaiani, F, additional, Marzo, M, additional, Luppino, I, additional, Paese, P, additional, Elisei, W, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Napolitano, D, additional, Grossi, L, additional, Serio, M, additional, Scarcelli, A, additional, Lorenzetti, R, additional, Allegretta, L, additional, Rocco, G, additional, Zampaletta, C, additional, Bolognini, L, additional, Meucci, C, additional, Colucci, R, additional, Tonti, P, additional, Della Valle, N, additional, Piga, R, additional, Forti, G, additional, Onidi, F M, additional, Usai Satta, P, additional, Picchio, M, additional, Papa, A, additional, and Tursi, A, additional

Published
2024
Full Text
View/download PDF

21. P442 Renal lithogenic risk in patients with Inflammatory Bowel Diseases correlates with microbiota composition, urinary profile and dietary intake

Author

Mignini, I, primary, Blasi, V, additional, Masucci, L, additional, De Maio, F, additional, Agrillo, C, additional, Monzo, F R, additional, Laterza, L, additional, Scaldaferri, F, additional, Napolitano, D, additional, Schiavoni, E, additional, D' Amato, D, additional, De Ninno, G, additional, Baroni, S, additional, Mele, M C, additional, Grassi, F, additional, Cintoni, M, additional, Garcovich, M, additional, Riccardi, L, additional, Gasbarrini, A, additional, Ferraro, P M, additional, and Papa, A, additional

Published
2024
Full Text
View/download PDF

22. P1213 The effects of Escherichia coli Nissle 1917 on the gut microbiota composition in ulcerative colitis patients

Author

Puca, P, primary, Del Chierico, F, additional, Graziani, C, additional, Masi, L, additional, Coppola, G, additional, Di Vincenz, F, additional, Capobianco, I, additional, Lopetuso, L R, additional, Barbaro, M R, additional, Masucci, L, additional, Putignani, L, additional, Petito, V, additional, Marasco, G, additional, Sanguinetti, M, additional, Barbara, G, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

23. P908 Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)

Author

Noviello, D, primary, Savarino, E, additional, Fries, W, additional, Fantini, M C, additional, Conforti, F, additional, Orlando, A, additional, Ribaldone, D G, additional, Mocci, G, additional, Viganò, C, additional, Festa, S, additional, Spagnuolo, R, additional, Campigotto, M, additional, Grossi, L, additional, Gravina, A G, additional, Principi, M, additional, Imperatore, N, additional, Carvalhas, A, additional, Scardino, G, additional, Scaldaferri, F, additional, Ceccarelli, L, additional, Biancone, L, additional, Di Sario, A, additional, De Barba, C, additional, De Francesco, C, additional, Calderone, S, additional, Onali, S, additional, Vecchi, M, additional, Ventimiglia, M, additional, and Caprioli, F, additional

Published
2024
Full Text
View/download PDF

24. P096 Human extrachromosomal circular DNA is an emerging biomarker in Inflammatory Bowel Disease

Author

Petito, V, primary, DI VINCENZO, F, additional, Gerovska, D, additional, Piazzesi, A, additional, Russo, A, additional, Turchini, L, additional, Masi, L, additional, Lopetuso, L R, additional, Abreu, M T, additional, Regenberg, B, additional, Gasbarrini, A, additional, Putignani, L, additional, Bravo Araúzo, M J, additional, and Scaldaferri, F, additional

Published
2024
Full Text
View/download PDF

25. P831 Acute infusion reactions due to different biologic agents in a large cohort of patients with Inflammatory Bowel Disease

Author

Colantuono, S, primary, Caruso, C, additional, Rumi, G, additional, Capobianco, I, additional, Blasi, V, additional, Termite, F, additional, Coppola, G, additional, Laterza, L, additional, Lopetuso, L R, additional, Mignini, I, additional, Napolitano, D, additional, Parisio, L, additional, Pugliese, D, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, and Papa, A, additional

Published
2024
Full Text
View/download PDF

26. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Author

Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., Scaldaferri F., Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., and Scaldaferri F.

Abstract

Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines. Results and conclusions Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.

Published
2023

28. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

31. OC.04.3 REAL-LIFE VS TRIAL ACCESS TO BIOLOGIC THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Author

Laterza, L., primary, Di Vincenzo, F., additional, Maresca, R., additional, Russo, M.C., additional, Mora, V., additional, Petito, V., additional, Turchini, L., additional, Amatucci, V., additional, Napolitano, D., additional, Schiavoni, E., additional, Settanni, C., additional, Parisio, L., additional, Pizzoferrato, M., additional, Lopetuso, L., additional, Armuzzi, A., additional, Gasbarrini, A., additional, Pugliese, D., additional, and Scaldaferri, F., additional

Published
2023
Full Text
View/download PDF

32. T.06.8 REAL WORD LONG-TERM EFFICACY AND SAFETY OF VEDOLIZUMAB IN MANAGING ULCERATIVE COLITIS VERSUS CROHN'S DISEASE: RESULTS FROM “LONG VEDO” ITALIAN MULTICENTER STUDY

Author

Mocci, G., primary, Maconi, G., additional, Cataletti, G., additional, Mantia, B., additional, Serio, M., additional, Scarcelli, A., additional, Onidi, F.M., additional, Pagnini, C., additional, Graziani, M., additional, Di Paolo, M., additional, Pranzo, G., additional, Luppino, I., additional, Paese, P., additional, Monterubbianesi, R., additional, Faggiani, R., additional, Ferronato, A., additional, Perini, B., additional, Savarino, E., additional, Binaghi, L., additional, Schiavoni, E., additional, Napolitano, D., additional, Scaldaferri, F., additional, Papa, A., additional, Lorenzetti, R., additional, Pica, R., additional, Cocco, A., additional, Rodino, S., additional, Sebkova, L., additional, Zampaletta, C., additional, Gaiani, F., additional, Fanigliulo, L., additional, Allegretta, L., additional, Cuomo, A., additional, Donnarumma, L., additional, Della Valle, N., additional, Forti, G., additional, Dore, M., additional, Antonelli, E., additional, Bassotti, G., additional, Iannelli, C., additional, Aragona, G., additional, Lauria, A., additional, Piergallini, S., additional, Colucci, R., additional, Meucci, C., additional, Usai Satta, P., additional, Elisai, W., additional, and Tursi, A., additional

Published
2023
Full Text
View/download PDF

33. Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

Author

Caruso, Cristiano, Laterza, Lucrezia, Settanni, Carlo Romano, Colantuono, S., Di Mario, Clara, Tolusso, Barbara, Castri, Federica, Gremese, Elisa, Scaldaferri, Franco, Armuzzi, Alessandro, De Simone, Clara, Peris, Ketty, Chiricozzi, Andrea, Gasbarrini, Antonio, Caruso C., Laterza L., Settanni C. R., Di Mario C., Tolusso B. (ORCID:0000-0002-9108-6609), Castri F., Gremese E. (ORCID:0000-0002-2248-1058), Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Gasbarrini A. (ORCID:0000-0002-7278-4823), Caruso, Cristiano, Laterza, Lucrezia, Settanni, Carlo Romano, Colantuono, S., Di Mario, Clara, Tolusso, Barbara, Castri, Federica, Gremese, Elisa, Scaldaferri, Franco, Armuzzi, Alessandro, De Simone, Clara, Peris, Ketty, Chiricozzi, Andrea, Gasbarrini, Antonio, Caruso C., Laterza L., Settanni C. R., Di Mario C., Tolusso B. (ORCID:0000-0002-9108-6609), Castri F., Gremese E. (ORCID:0000-0002-2248-1058), Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

We described a case of IPEX syndrome successfully controlled with dupilumab, an anti-IL4 receptor alpha subunit inhibitor. IPEX syndrome is a rare and generally fatal genetic disorder characterized by immune dysregulation, polyendocrinopathy and enteropathy, mostly diagnosed in early childhood. Nonetheless, cases reported in the last 20 years demonstrated that IPEX clinical spectrum encompasses more than the classical triad of early-onset intractable diarrhea, type 1 diabetes and eczema. Atypical cases of IPEX include patients with late-onset of symptoms, single-organ involvement, mild disease phenotypes or rare clinical features. A 21-year-old caucasian man presented with immune dysregulation (hypereosinophilia and elevated IgE), protein-losing enteropathy, polyendocrinopathy (thyroiditis, osteoporosis, delayed puberty), weight loss, eczema manifestations and celiac disease. IPEX syndrome was diagnosed because of the presence of a hemizygous mutation in FOXP3 gene (c.543C>T (p.S181S) in the exon 5). During the course of the disease, the patient developed erosive proctitis, pyoderma gangrenosum, and erythema nodosum. Symptoms improved only after enteral and parenteral corticosteroid therapy and the patient soon developed steroid-dependence. Notwithstanding various therapies including azathioprine, sirolimus, tacrolimus, adalimumab, vedolizumab, the patient failed to achieve a good control of symptoms without steroids. Almost exclusive enteral nutrition with a hypoallergenic, milk-protein free, amino acid-based food for special medical purposes. He continued to lose weight (BMI 14.5 kg/m2) with a consequent high limitation of physical activity and a progressive worsening of the quality of life. In consideration of the poor response to conventional immunosuppressants and the presence of type 2 inflammatory manifestations, treatment with dupilumab at an initial dose of 600 mg, followed by a maintenance dose of 300 mg every other week, according to atopic dermatitis

Published
2023

38. P828 Incidence and predictors of arterial and venous thromboembolic events in hospitalized patients with inflammatory bowel disease compared to patients with acute infective gastroenteritis and colitis: a propensity score-matched study

Author

Papa, A, primary, Lopetuso, L R, additional, Mignini, I, additional, Settanni, C R, additional, Scaldaferri, F, additional, Pugliese, D, additional, Laterza, L, additional, Covino, M, additional, Franceschi, F, additional, and Gasbarrini, A, additional

Published
2023
Full Text
View/download PDF

40. P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study

Author

Mocci, G, primary, Maconi, G, additional, Onidi, F M, additional, Cataletti, G, additional, Elisei, W, additional, Scaldaferri, F, additional, Lorenzetti, R, additional, Pagnini, C, additional, Scarcelli, A, additional, Graziani, M G, additional, Di Paolo, M C, additional, Pranzo, G, additional, Luppino, I, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Ferronato, A, additional, Savarino, E, additional, Pica, R, additional, Cocco, A, additional, Rodino, S, additional, Sebkova, L, additional, Zampaletta, C, additional, Gaiani, F, additional, Fanigliulo, L, additional, Allegretta, L, additional, Cuomo, A, additional, Donnarumma, L, additional, Della Valle, N, additional, Forti, G, additional, Antonelli, E, additional, Bassotti, G, additional, Iannelli, C, additional, Aragona, G, additional, Lauria, A, additional, Piergallini, S, additional, Colucci, R, additional, Binaghi, L, additional, Meucci, C, additional, Papa, A, additional, and Tursi, A, additional

Published
2023
Full Text
View/download PDF

41. N14 The satisfaction of IBD patients’ nursing care in biological therapy. Observational study

Author

Napolitano, D, primary, Cocchieri, A, additional, Orgiana, N, additional, Fanali, C, additional, Poscia, A, additional, Schiavoni, E, additional, Bernabei, T, additional, Amatucci, V, additional, Turchini, L, additional, Durini, E, additional, Strazzeri, M, additional, Laterza, L, additional, Lopetuso, L R, additional, Mora, V, additional, Papa, A, additional, Pugliese, D, additional, Gasbarrini, A, additional, and Scaldaferri, F, additional

Published
2023
Full Text
View/download PDF

42. N04 How to manage the concerns of patients with inflammatory bowel disease due to the transition from in-hospital to home management with oral or subcutaneous therapies: results of a survey of a cohort of patients in intravenous biologic treatment

Author

Napolitano, D, primary, Settanni, C R, additional, Parisio, L, additional, Schiavoni, E, additional, Pugliese, D, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, and Papa, A, additional

Published
2023
Full Text
View/download PDF

43. Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

Author

Caruso, C., primary, Laterza, L., additional, Settanni, C. R., additional, Colantuono, S., additional, Di Mario, C., additional, Tolusso, B., additional, Castrì, F., additional, Gremese, E., additional, Scaldaferri, F., additional, Armuzzi, A., additional, De Simone, C., additional, Peris, K., additional, Chiricozzi, A., additional, and Gasbarrini, A., additional

Published
2023
Full Text
View/download PDF

44. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

45. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study

Author

Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Armuzzi A. (ORCID:0000-0003-1572-0118), Orlando A., Felice C., Pugliese D., Allocca M., Ferretti F., Giuliano A., Buda A., Casella G., Onali S., Spagnuolo R., Baldoni M., Scaldaferri F. (ORCID:0000-0001-8334-7541), Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Armuzzi A. (ORCID:0000-0003-1572-0118), Orlando A., Felice C., Pugliese D., Allocca M., Ferretti F., Giuliano A., Buda A., Casella G., Onali S., Spagnuolo R., Baldoni M., and Scaldaferri F. (ORCID:0000-0001-8334-7541)

Abstract

Background: Older age and comorbidities are the main risk factors for adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims: To assess risk factors for adverse outcomes of COVID-19 in IBD patients and use the identified risk factors to build risk indices. Methods: Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results: Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS-CoV-2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID-19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune-mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID-19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID-19 outcomes, but anti-TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID-19 in CD. Conclusion: The course of COVID-19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID-19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID-19 re-vaccination or for therapies for SARS-CoV-2 infection.

Published
2021

46. Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy

Author

Privitera, G., Pugliese, D., Onali, S., Petito, V., Scaldaferri, F., Gasbarrini, A., Danese, S., Armuzzi, A., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, G., Pugliese, D., Onali, S., Petito, V., Scaldaferri, F., Gasbarrini, A., Danese, S., Armuzzi, A., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

Background: Combining immunosuppressors has been proposed as a strategy to enhance treatment efficacy in Inflammatory Bowel Disease (IBD). Aim: To summarize current evidence on combinations of targeted therapies with traditional immunosuppressors or with other targeted therapies. Methods: A literature search on PubMed and Medline databases was performed to identify relevant articles. Results: Current evidence supports that the combination of infliximab and thiopurines is more effective than monotherapy with both agents in inducing remission in Crohn's Disease and Ulcerative colitis. Data on other combinations of other biologics and traditional immunosuppressors is lacking or show conflicting results. Vedolizumab seems a potentially effective maintenance regimen after calcineurin inhibitors-based rescue therapy in acute severe ulcerative colitis, as an alternative to thiopurines. Dual Targeted Therapy, which is the combination of 2 targeted therapies, might be a reasonable choice in patients with concomitant IBD and extraintestinal manifestations, or in patients with medical-refractory IBD who lack valid alternatives. Combinations with thiopurines are associated with an increased risk of infections and lymphoma. Data on other combinations is scarcer, but no specific safety issue has emerged so far. Conclusions: Combination therapies seem to be effective in selected patients, with an overall acceptable safety profile.

Published
2021

47. Bariatric procedures and microbiota: patient selection and outcome prediction

Author

Puca, P., Petito, V., Laterza, L., Lopetuso, L. R., Neri, M., Del Chierico, F., Boskoski, I., Gasbarrini, A., Scaldaferri, F., Puca P., Petito V., Laterza L., Lopetuso L. R., Neri M., Boskoski I. (ORCID:0000-0001-8194-2670), Gasbarrini A. (ORCID:0000-0002-7278-4823), Scaldaferri F. (ORCID:0000-0001-8334-7541), Puca, P., Petito, V., Laterza, L., Lopetuso, L. R., Neri, M., Del Chierico, F., Boskoski, I., Gasbarrini, A., Scaldaferri, F., Puca P., Petito V., Laterza L., Lopetuso L. R., Neri M., Boskoski I. (ORCID:0000-0001-8194-2670), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Scaldaferri F. (ORCID:0000-0001-8334-7541)

Abstract

Obesity is a major health issue throughout the world and bariatric surgery plays a key role in its management and treatment. The role of microbiota in determining the pathogenesis of obesity has been widely studied, while its role in determining the outcome of bariatric surgery is an emerging issue that will be an outcome in near future studies. Studies on mice first showed the key role of microbiota in determining obesity, highlighting the fat mass increase in mice transplanted with microbiota from fat individuals, as well as the different microbiota composition between mice undergone to low-fat or high-fat diets. This led to characterize the asset of microbiota composition in obesity: increased abundance of Firmicutes, reduced abundance of Bacteroidetes and other taxonomical features. Variations on the composition of gut microbiome have been detected in patients undergone to diet and/or bariatric surgery procedures. Patients undergone to restricting diets showed lower level of trimethylamine N-oxide and other metabolites strictly associated to microbiome, as well as patients treated with bariatric surgery showed, after the procedure, changes in the relative abundance of Bacteroidetes, Firmicutes and other phyla with a role in the pathogenesis of obesity. Eventually, studies have been led about the effects that the modification of microbiota could have on obesity itself, mainly focusing on elements like fecal microbiota transplantation and probiotics such as inulin. This series of studies and considerations represent the first step in order to select patients eligible to bariatric surgery and to predict their outcome.

Published
2021

48. The role of enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases

Author

Baldelli, V., Scaldaferri, F., Putignani, L., Del Chierico, F., Scaldaferri F. (ORCID:0000-0001-8334-7541), Putignani L., Baldelli, V., Scaldaferri, F., Putignani, L., Del Chierico, F., Scaldaferri F. (ORCID:0000-0001-8334-7541), and Putignani L.

Abstract

Inflammatory bowel diseases (IBDs) are a group of chronic gastrointestinal inflammatory diseases with unknown etiology. There is a combination of well documented factors in their pathogen-esis, including intestinal microbiota dysbiosis. The symbiotic microbiota plays important functions in the host, and the loss of beneficial microbes could favor the expansion of microbial pathobionts. In particular, the bloom of potentially harmful Proteobacteria, especially Enterobacteriaceae, has been described as enhancing the inflammatory response, as observed in IBDs. Herein, we seek to investigate the contribution of Enterobacteriaceae to IBD pathogenesis whilst considering the continuous expansion of the literature and data. Despite the mechanism of their expansion still remaining unclear, their expansion could be correlated with the increase in nitrate and oxygen levels in the inflamed gut and with the bile acid dysmetabolism described in IBD patients. Furthermore, in several Enterobacteriaceae studies conducted at a species level, it has been suggested that some adherent-invasive Escherichia coli (AIEC) play an important role in IBD pathogenesis. Overall, this review highlights the pivotal role played by Enterobacteriaceae in gut dysbiosis associated with IBD pathogenesis and progression.

Published
2021

49. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center

Author

Ianiro, G., Bibbo, S., Porcari, S., Settanni, C. R., Giambo, F., Curta, A. R., Quaranta, G., Scaldaferri, F., Masucci, L., Sanguinetti, M., Gasbarrini, A., Cammarota, G., Ianiro G. (ORCID:0000-0002-8318-0515), Porcari S., Settanni C. R., Quaranta G., Scaldaferri F. (ORCID:0000-0001-8334-7541), Masucci L. (ORCID:0000-0002-8358-6726), Sanguinetti M. (ORCID:0000-0002-9780-7059), Gasbarrini A. (ORCID:0000-0002-7278-4823), Cammarota G. (ORCID:0000-0002-3626-6148), Ianiro, G., Bibbo, S., Porcari, S., Settanni, C. R., Giambo, F., Curta, A. R., Quaranta, G., Scaldaferri, F., Masucci, L., Sanguinetti, M., Gasbarrini, A., Cammarota, G., Ianiro G. (ORCID:0000-0002-8318-0515), Porcari S., Settanni C. R., Quaranta G., Scaldaferri F. (ORCID:0000-0001-8334-7541), Masucci L. (ORCID:0000-0002-8358-6726), Sanguinetti M. (ORCID:0000-0002-9780-7059), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Cammarota G. (ORCID:0000-0002-3626-6148)

Abstract

Inflammatory bowel disease (IBD) is a risk factor for C. difficile infection (CDI), which, in turn, complicates the clinical course of IBD. Fecal microbiota transplantation (FMT) is safe and effective in patients with IBD and recurrent CDI (rCDI). In our study, patients with IBD and rCDI received FMT by colonoscopy and were followed-up for 8 weeks. The primary outcome was negative C. difficile toxin 8 weeks after FMT. Eighteen patients with IBD were enrolled. Eight patients received sequential FMT either for pseudomembranous colitis or failure of single fecal infusion. At 8-week follow-up the C. difficile toxin was negative in 17 patients, and most (83%) experienced also improvement of IBD disease activity. Overall, we did not observe any serious adverse event. FMT appears to be highly effective and safe in patients with IBD and rCDI and is likely not only to eradicate CDI but also to improve disease activity of IBD.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results